The Cardiothoracic Surgical Trials Network is part of NIH’s infrastructure for conducting clinical trials in cardiac surgery. The Keck School of Medicine of the University of Southern California recently received $4.5 million from the NIH and National Heart Lung and Blood Institute (NHLBI) to fund efforts in recruiting underrepresented groups to clinical trials—with a focus on Hispanic (Latino) populations in Los Angeles. Michael Bowdish, MD, MS, associate professor of surgery and preventive medicine at the Keck School of Medicine recently commented on their efforts for greater inclusiveness.
In an interview with Healio Dr. Bowdish reported that “By increasing patient diversity in cardiac surgery clinical trials, we are better suited to address cardiovascular disease, the number one cause of mortality in the United States.”
Access Represents the Greatest Barrier
Dr. Bowdish noted to Healio that access was the largest barrier to greater participation of underrepresented minorities such as Hispanics or African Americans. Dr. Bowdish emphasized that as USC is part of the Cardiothoracic Surgical Trials Network they are able to bring state-of-the-art clinical trials in cardiac surgery to the largely Hispanic population served by Los Angeles County and University of Southern California (USC) Medical Center.
Follow the link to the source at Healio for the rest of the important interview.
The Cardio Surgical Trials Network
The Cardio Surgical Trials Network was set up to foster a culture of rigorous scientific comparisons and to promote the evaluation of newer surgical techniques, devices, and innovative pharmaceutical and bioengineered products directed at improving cardiovascular disease outcomes in adult populations.
With support from the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), and the Canadian Institutes of Health Research (CIHR), the CTSN provides the infrastructure to develop, coordinate, and conduct multiple collaborative proof-of-concept studies and interventional protocols to improve cardiovascular disease outcomes. Their network enables interdisciplinary research teams led to evaluate therapies and techniques as they move from laboratory science to broad clinical use. Interested in reading up on their past research? See their newsletters.
Michael Bowdish, MD, MS, Associate Professor of Surgery and Preventive Medicine at the Keck School of Medicine
Call to Action: Are you a sponsor seeking to ensure greater inclusivity in your clinical studies? We recommend partner with Keck who has a tremendous track record of introducing innovative programs to ensure greater clinical trial participant diversity.Source: Healio